Deinove's contribution to the subsidiary are the results and intellectual property rights relating to research undertaken on antibiotics, as well as the transfer of the OSEO-ERDF-LR region funding already allocated – €700,000 (US$908,857...would entitle pSivida to a $25 million milestone payment from Alimera and 20 percent of net profits

Ltd., enabling Simcere Vaxtec to resume production of its influenza vaccine

In separate news, Astellas signed a deal to access the TSUBAME2.0 supercomputer at the Tokyo Institute of Technology to discover candidates for NTDs caused by dengue virus

Cancer Research Technology, the commercial arm of Cancer Research UK, and the Institute of Cancer Research, London, said they were collaborating with Janssen Biotech Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, to discover a potential new multiple myeloma drug

Another $13 million to $15 million in equipment, integration service and testing will be provided by Agila...The resolution would authorize the board to effect a share consolidation at a rate of up to 10 to 1...The compounds are thought to have relevance for Parkinson's disease

The FDA stated that bleeding rates associated with new use of Pradaxa do not appear to be higher than those with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial

Sosei licensed Japanese rights to the compound from BioAlliance, which markets the product as Loramyc/Oravig...The studies are designed to allow PCT to evaluate the applicability of SistemQC technology in stem cell characterization employing Sistemic's miRNA profiling system and analytical approaches to product miRNA panels

The parties agreed to a settlement payment of $40 million, $38 million of which will be funded by Dendreon's insurers...sales and distribution rights to Abstral (fentanyl) sublingual tablets from Orexo AB, of Uppsala, Sweden...An independent assessment to confirm the diagnosis and evaluate the cause is planned

Save for Wolbern Private Equity GmbH (WPE), no other partner who took part in the formal sale process made an offer, and WPE later withdrew its offer...Ark has been struggling to keep itself afloat since 2010, when the European Medicines Agency rejected gene therapy candidate Cerepro for use in glioma...Vanda said it intends to reassess its European regulatory strategy once those results become available

In other news, law firm Bronstein, Gewirtz & Grossman LLC, of New York, said it is investigating claims on behalf of purchasers of Spectrum securities, after shares (NASDAQ:SPPI) fell as much as 38 percent on March 13 on news that the company slashed its revenue projections for colon cancer drug Fusilev (levoleucovorin

Astellas Pharma Inc., of Tokyo, said the European Commission approved expanded options for pre-treatment prior to use of Qutenza (8 percent capsaicin patch

Inc., of Whitehouse Station, N.J., and Luminex Corp., of Austin, Texas, signed a collaboration and license deal to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, an oral, beta amyloid precursor protein site cleaving enzyme inhibitor and Merck's lead candidate for Alzheimer's disease...Takeda Pharmaceutical Co., of Tokyo, and the Scripps Research Institute announced plans to expand their

That news "shocked the Street," according to Roth Capital Partners analyst Joseph Pantginis...Investors took the news hard, sending shares of Spectrum (NASDAQ:SPPI) falling $4.64, or 37.3 percent, to close Wednesday at $7.79

In the same study, ANAVEX 2-73 also blocked apoptosis and oxidative stress, which is believed to prevent the onset of Alzheimer's...CMX001 is a broad-spectrum, oral nucleotide analogue lipid-conjugate designed to block the replication of double-stranded DNA viruses...That cross-border supply approval is in addition to the manufacturing capacity in the UK already developed with partner Kings College London

and other affiliates he controls, proposing to acquire outstanding shares not currently owned by the group for $9.56 per American Depositary Share (ADS) or $4.78 per ordinary shares in cash...Simcere's board formed a special committee of independent directors to evaluate the offer

Eisai Inc., of Woodcliff Lake, N.J., reported that the German Federal Joint Committee said it considers the additional benefit of Fycompa (perampanel) unproven when compared to two other treatments...Eisai said it believes the committee "failed to adequately interpret" benefits to patients with the drug, which is indicated as an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy, age 12 and older

Tecafarin recently completed a Phase III study showing it was safe and effective in patients with prosthetic heart valves in addition to patients with other conditions such as atrial fibrillation or venous thromboembolism, independent of CYP status...In addition to strengthening its balance sheet, Biovest said the move will support ongoing strategies to commercialize its BiovaxID personalized cancer vaccine, including facilitating ongoing partnering/licensing initiatives, as well as enhancing the

The company has also submitted new drug applications to the FDA for canagliflozin and for the fixed-dose combination therapy...The companies will expand their existing collaboration to include joint promotion of Abilify in Denmark, Finland, Germany, Italy, Spain, Sweden and the U.K. Lundbeck will promote Abilify in Austria, Belgium, Ireland, Netherlands, Poland, Portugal and Romania...Under the agreement, Lundbeck will have the right to promote all formulations of Abilify currently marketed, sold or

to develop, manufacture and supply commercial quantities of Ofirmev (acetaminophen) injection in flexible plastic bags...According to the terms of an asset purchase agreement jointly executed by the parties, RXi will acquire substantially all of OPKO's RNAi-related assets, including an extensive intellectual property portfolio...Sorrento Therapeutics Inc., of San Diego, signed an exclusive option to acquire Igdrasol Inc., of Fountain Valley, Calif., a private company focused on the development of